title: Patterns of oral anticoagulants use in atrial fibrillation.
abstract: BACKGROUND
  Novel oral anticoagulants are available for the management of atrial fibrillation and are considered more convenient to use than warfarin.
  
  
  OBJECTIVE
  The main objective of this study was to describe patterns of oral anticoagulant use in the 6 months period following the availability of dabigatran at our hospital.
  
  
  METHODS
  A cross-sectional study was conducted in a single University hospital in the province of Québec, Canada. Medical records of subjects on oral anticoagulants for atrial fibrillation that were hospitalized between October 1st, 2011 and March 31th, 2012 were reviewed. Type of use (prevalent, incident and switch) and patient's characteristics of warfarin and dabigatran users were compared using Chi-squared and T-tests.
  
  
  RESULTS
  In the 6-month period following dabigatran availability in the hospital, 59 patients (13%) were on dabigatran and 388 (87%) on warfarin. Mean CHADS2 score, mean age and mean number of chronic medications were lower in the dabigatran group. The percentage of patients with coronary artery disease was lower and renal function was higher in the dabigatran group.
  
  
  CONCLUSIONS
  Dabigatran use remained low in the first 6 months period following the approval of dabigatran at our hospital, which could be explained by limited data on the efficacy and safety of this agent in subjects with multiple comorbidities.
authors.forename: C
authors.initials: C
authors.lastname: Brais
authors.forename: J
authors.initials: J
authors.lastname: Larochelle
authors.forename: Mh
authors.initials: M
authors.lastname: Turgeon
authors.forename: As
authors.initials: A
authors.lastname: Tousignant
authors.forename: L
authors.initials: L
authors.lastname: Blais
authors.forename: S
authors.initials: S
authors.lastname: Perreault
authors.forename: P
authors.initials: P
authors.lastname: Farand
authors.forename: G
authors.initials: G
authors.lastname: Letemplier
authors.forename: Mf
authors.initials: M
authors.lastname: Beauchesne
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000600:supply & distribution / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D001562:Benzimidazoles / Q000009:adverse effects / Q000600:supply & distribution / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D000069604:Dabigatran; D057915:Drug Substitution; D017723:Drug Utilization Review; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008297:Male; D010818:Practice Patterns, Physicians' / Q000639:trends*; D011792:Quebec; D012189:Retrospective Studies; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects / Q000600:supply & distribution / Q000627:therapeutic use*; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000600:supply & distribution / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran